Clovis Oncology (CLVS) Misses Q3 EPS by 11c

Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60). Revenue for the quarter came in at $22.76 million versus the consensus estimate of $30.11 million.

“As discussed last quarter, growth remains challenging in the second-line maintenance ovarian cancer setting, but we have efforts underway to address this and we are aggressively moving forward to grow this market and grow our share of this market,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “In addition, our development team continues to make significant progress in moving Rubraca beyond its initial ovarian cancer indications. In particular, we were very pleased with the data from the TRITON studies presented at ESMO and at the Prostate Cancer Foundation Scientific Retreat, which also served as the basis for Breakthrough Therapy designation, and we are committed to developing Rubraca in the prostate setting as rapidly as possible to support men with this difficult-to-treat disease.”

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Stantec (STN) Tops Q2 EPS by 47c
• Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03